USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
21 Sep 2021 | 02:45 PM GMT

Sprint: Prescription DTx - Commercialization Models & Adoption

Anchored by:

Lee Shapiro
Managing Partner
7WIREVENTURES
Zina Manji
Founder/Principal, Regulatory Strategist
INNOPATHWAYZ, LLC

Participants:

Lee Shapiro Managing Partner7wireVentures
Lee Shapiro
Managing Partner7wireVentures
Zina Manji Founder/Principal, Regulatory StrategistInnopathwayz, LLC
Zina Manji
Founder/Principal, Regulatory StrategistInnopathwayz, LLC
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Aahuti Rai NED & Venture PartnerFour Points Health
Aahuti Rai
NED & Venture PartnerFour Points Health
Ashley Mateus VP Consumer InsightsAkili Interactive Labs
Ashley Mateus
VP Consumer InsightsAkili Interactive Labs
Brendan Staunton CEOAmara Therapeutics
Brendan Staunton
CEOAmara Therapeutics
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
Francesca Wuttke Founder & CEOnen Health
Francesca Wuttke
Founder & CEOnen Health
Jeff Berkowitz CEORealEndpoints
Jeff Berkowitz
CEORealEndpoints
JM
john mattison CMIOACP
JM
john mattison
CMIOACP
Joseph Rubinsztain CEOChronWell
Joseph Rubinsztain
CEOChronWell
Justin Norden PartnerGSR Ventures
Justin Norden
PartnerGSR Ventures
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Mike Pace Founder & CEOPalmHealthCo
Mike Pace
Founder & CEOPalmHealthCo
Robert Garber Managing Partner7wireVentures
Robert Garber
Managing Partner7wireVentures

About this Meeting

In the past 2 years a wide variety of companies have co-opted the term “DTx” to describe their digital health offerings. In this meeting we want to focus on a smaller subset of this group: prescription digital therapeutics (PDTs), which are seen as the future of the DTx market. This series of 2 meetings to discuss with other senior leaders the following: 

  •  Session 1 (September 1st): Commercialization models Even though some PDT companies choose the traditional pharmaceutical pathway (salesforce-based), are Pharma-PDT partnerships the best efficient commercialization model for PDT companies? What are the alternatives? New consumer-focused telemedicine approaches to PDT distribution have recently entered the market. What are the pros & cons of this model?  How does the prescription pathway influence the product pricing? 
  •  Session 2 (September 21st): Adoption  As PDTs are edging closer to becoming incorporated into therapeutic arsenals, the seamless integration into conventional pathways still needs to be ironed out. How can digital health formularies and/or prescription platforms help in PDT adoption?  In some countries, there is prescription capability (e.g Germany, UK), but current prescription rates are still low. What are the next steps to increase PDT prescription and adoption?